The August edition of Ophthalmology has revealed an astounding study wherein investigators from the Tokyo Medical & Dental Univ. have reported on the foremost definite ‘map’ of myopic maculopathy, an ailment which afflicts several people with acute nearsightedness. The study additionally examines the map as a means of forecasting which patients having myopic maculopathy have the maximum likelihood of suffering from vision loss due to the condition.
The uncomplicated ease of access to the eyes and the proven association in-between particular heritable flaws and visual disorders proffer sanguinity for deploying gene therapy to garner long-standing curative gains.
Duo studies appearing in the peer-assessed journal ‘Human Gene Therapy’ illustrate the effectual substitution of a human gene for preserving photoreceptor utility in rodent model of acute retinal degeneration.
Study researchers distributed the human gene for RGPR –interacting protein-1 to rodents afflicted with LCA also known as Leber congenital amaurosis. It is an eye condition associated with an altered type of RPGRIP1 which is causal to photoreceptor de-generation in the eyes.
The investigators did the packaging of the gene in an AAV (or adeno-associated virus) vector and then administered it underneath the retinal areas of the afflicted rodents. They illustrated human gene being expressed in the photoreceptors alongside accurate cilial localisation. Additional assessment exhibited enhanced functioning and photoreceptors managing to survive in the eye that underwent treatment.
The study researchers arrived at a conclusion that their research validates a gene therapy plan which can provide the foundation for imminent scientific study among patients afflicted with such a type of LCA.
Another study by researchers at Univ. of Massachusetts Medical School reviewed the usage of re-combinant adeno-associated virus vectors in gene therapy for treating visual conditions. On the basis of successful outcomes of trio early staging scientific studies in leber congenital amaurosis, the researchers concluded that the rAAV mediated gene therapy is an apt, safe and effectual therapy approach for visual disorders like LCA.
The triumphant rectification of such photoreceptor flaw in pertinent rodent model having LCA could shepherd in a novel beckon of conversional study in retinal degeneration disorders.
